Early Phase Clinical Trial Units (EPCTU)

This pre-solicitation notice seeks multiple Indefinite Delivery/Indefinite Quantity contracts to support Phase 0 through Phase II clinical trials of investigational products against infectious diseases through the National Institute of Allergy and Infectious Diseases. Contractors will collaborate with monitoring and data management partners to conduct domestic and international trials efficiently under a January 2022 anticipated award date and seven-year ordering period. Eligible offerors may submit proposals via the NIH electronic submission system for consideration to support the full range of early phase clinical trial activities, including administrative support, Phase 0 healthy volunteer studies, Phase I healthy volunteer studies, Phase I special population studies, and Phase II or III patient studies.

There is no set-aside designation. The main NAICS codes are 541715 and 541712, with PSC codes R425 and R499. No potential incumbents or current contractors are named. The pre-solicitation notice does not provide possible award values or budget ranges. Contractors will support Phase 0 through Phase III clinical trials of investigational infectious disease products over a seven-year ordering period beginning in January 2022.